bTUNED: transcutaneous tibial nerve stimulation for neurogenic lower urinary tract dysfunction.
Détails
Télécharger: 37204144.pdf (1028.14 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_10032C0C2BD6
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
bTUNED: transcutaneous tibial nerve stimulation for neurogenic lower urinary tract dysfunction.
Périodique
BJU international
ISSN
1464-410X (Electronic)
ISSN-L
1464-4096
Statut éditorial
Publié
Date de publication
09/2023
Peer-reviewed
Oui
Volume
132
Numéro
3
Pages
343-352
Langue
anglais
Notes
Publication types: Clinical Trial Protocol ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
To present the protocol for a randomized controlled trial (RCT) evaluating the efficacy and safety of transcutaneous tibial nerve stimulation (TTNS) for refractory neurogenic lower urinary tract dysfunction (NLUTD).
bTUNED (bladder and TranscUtaneous tibial Nerve stimulation for nEurogenic lower urinary tract Dysfunction) is an international multicentre, sham-controlled, double-blind RCT investigating the efficacy and safety of TTNS. The primary outcome is success of TTNS, defined as improvements in key bladder diary variables at study end compared to baseline values. The focus of the treatment is defined by the Self-Assessment Goal Achievement (SAGA) questionnaire. Secondary outcomes are the effect of TTNS on urodynamic, neurophysiological, and bowel function outcome measures, as well as the safety of TTNS.
A total of 240 patients with refractory NLUTD will be included and randomized 1:1 into the verum or sham TTNS group from March 2020 until August 2026. TTNS will be performed twice a week for 30 min during 6 weeks. The patients will attend baseline assessments, 12 treatment visits and follow-up assessments at the study end.
bTUNED (bladder and TranscUtaneous tibial Nerve stimulation for nEurogenic lower urinary tract Dysfunction) is an international multicentre, sham-controlled, double-blind RCT investigating the efficacy and safety of TTNS. The primary outcome is success of TTNS, defined as improvements in key bladder diary variables at study end compared to baseline values. The focus of the treatment is defined by the Self-Assessment Goal Achievement (SAGA) questionnaire. Secondary outcomes are the effect of TTNS on urodynamic, neurophysiological, and bowel function outcome measures, as well as the safety of TTNS.
A total of 240 patients with refractory NLUTD will be included and randomized 1:1 into the verum or sham TTNS group from March 2020 until August 2026. TTNS will be performed twice a week for 30 min during 6 weeks. The patients will attend baseline assessments, 12 treatment visits and follow-up assessments at the study end.
Mots-clé
Humans, Tibial Nerve/physiology, Transcutaneous Electric Nerve Stimulation/methods, Treatment Outcome, Urinary Bladder, Urinary Bladder, Overactive, Randomized Controlled Trials as Topic, clinical trial protocol, neuro-urology, neurogenic detrusor overactivity, neurogenic lower urinary tract dysfunction, neuromodulation, tibial nerve stimulation, transcutaneous tibial nerve stimulation
Pubmed
Web of science
Open Access
Oui
Création de la notice
24/05/2023 7:56
Dernière modification de la notice
09/02/2024 8:43